Homepage Top Section2

Carvykti is intended to treat adults with relapsed or refractory multiple myeloma who have previously received a minimum of one line of therapy including a proteasome inhibitor, an

Under a new license and supply agreement, Celltrion will supply adalimumab biosimilar drug substance CT-P17 that is required for RT-105. Rani has an exclusive license to use the

The designation was granted based on the results from an ongoing Phase Ib/II study of olverembatinib carried out in China. The study demonstrated a clinical benefit rate of

Tabuk is a fully owned subsidiary of Astra Industrial Group. Under the agreement, Tabuk will hold the marketing authorisation and will be responsible for registering, importing, and commercialising

The designation for the investigational gene therapy was granted based on positive safety and efficacy data from the Phase I study in patients with Danon Disease. A favourable

The fundraise saw the participation of new and existing investors Kineticos Ventures and MVM Partners, respectively. Kineticos Ventures president and CEO Frank Lis is joining eXmoor board as

Abiogen Pharma’s business spans across many integrated aspects: research and development, manufacturing of pharmaceuticals under its own brand or third-party contracts, and marketing of its own and licensed

This recommendation is for ZTALMY to serve as the adjunctive treatment of epileptic seizures related with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17

VMX-C001 is a modified recombinant human blood clotting factor X that enables patients taking direct oral anticoagulant blood thinners to undergo emergency surgery without the risk of bleeding.